MyoGene Bio is Committed to Developing Cutting Edge Therapies for Muscle Diseases
Our lead program, MyoDys45-55, is an effective gene editing treatment for the devastating, fatal disease, Duchenne muscular dystrophy
Embedded Files
Duchenne muscular dystrophy has no cure but ongoing research and clinical trials finally offer hope for this devastating muscle wasting disease. MyoDys45-55 is designed to permanently fix the underlying cause of the disease for half of all Duchenne patients using this single platform. Future programs will develop similar strategies for more patients and other muscle diseases. MyoGene Bio’s goal is to have a significant impact on disease progression for devastating muscle disorders.
MyoGene Bio is selected for TechCrunch Disrupt Startup Battlefield
August 24, 2026
MyoGene Bio is excited to have been selected out of thousands of applicants to participate in Startup Battlefield 200 at TechCrunch Disrupt 2026.
MyoGene Bio Receives Venture Philanthropy and Angel Investment
November 4, 2025
MyoGene is pleased to report investment from angel investors and venture philanthropy groups of $1.42M.
MyoGene Bio is Granted Orphan Drug and Rare Pediatric Disease Designations
November 19, 2024
MyoGene is pleased to announce that FDA has granted Orphan Drug Designation and Rare Pediatric Disease Designation to MyoDys45-55 for Duchenne muscular dystrophy.
Page updated
Report abuse